BRD4 and prostate cancer: Abnormal transcription activities driven by SEs, such as cyclin dependent kinase 7 (CDK7), bromodomain and extra-terminal domain (BET)/bromodomain containing 4 (BRD4), and androgen receptor (AR), have been reported to influence prostate cancer phenotypes[8].